RIPK3 and neoplasm: Moreover, some chemokines released from necroptotic cells can in fact support pro-cancerous processes, e.g., RIPK3/RIPK1-driven CXCL1 in pancreatic cancer can facilitate tumor progression (via TAMs and MDSCs) by restricting infiltration of highly immunogenic T or B cells [252].